BMJ3d
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs
The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental ...
BMJ2d
Single-cell transcriptomics reveal potent extrafollicular B cell response linked with granzyme K + CD8 T cell activation in lupus kidney
2 Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China 3 University of Chinese Academy of Sciences, Beijing, ...
BMJ6d
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ5d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
4 Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Universidade de Lisboa, and Centro Académico deMedicina de Lisboa, Lisbon, Portugal 5 Oxford NIHR Biomedical Research Centre ...
BMJ2d
Tumour-like mass lesion: an under-recognised presentation of primary angiitis of the central nervous system
Eamonn S Molloy, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; molloye{at}ccf.org Objective ...
BMJ4d
Studies with pain rating scales.
Good correlation has been shown between pain scores derived from 4 different rating scales. The correlation was maintained when presentation of the scales was separated by a series of questions and by ...
BMJ5d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ6d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ12d
Senescent cell population with ZEB1 transcription factor as its main regulator promotes osteoarthritis in cartilage and meniscus
Objectives Single-cell level analysis of articular cartilage and meniscus tissues from human healthy and osteoarthritis (OA) knees. Methods Single-cell RNA sequencing (scRNA-seq) analyses were ...
BMJ4d
Methotrexate: what are the true risks of treatment?
For more than three decades, low-dose methotrexate (MTX) has been the first-line treatment for patients with rheumatoid arthritis (RA). Even after the introduction of biologics/biosimilars and janus ...
BMJ4d
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or ...
BMJ5d
Painful shoulder: comparison of physical examination and ultrasonographic findings
Background: High frequency ultrasonography is an accurate non-invasive imaging technique for evaluating patients with painful shoulder. Objective: To compare the clinical diagnosis established by a ...